Hyoung Kim, Erin George, Ryan Ragland, Stavros Rafail, Rugang Zhang, Clemens Krepler, Mark Morgan, Meenhard Herlyn, Eric Brown, Fiona Simpkins. Clin Cancer Res 2017
Times Cited: 179
Times Cited: 179
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong, Wenting Wu, Carsten Goessl, Sarah Runswick, Pierfranco Conte. N Engl J Med 2017
Times Cited: 1517
Times Cited: 1517
List of shared articles
Times cited
Systemic Therapy for Hereditary Breast Cancers.
Elizabeth J Harvey-Jones, Christopher J Lord, Andrew N J Tutt. Hematol Oncol Clin North Am 2023
Elizabeth J Harvey-Jones, Christopher J Lord, Andrew N J Tutt. Hematol Oncol Clin North Am 2023
Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
Yongsong Wu, Shilin Xu, Shanshan Cheng, Jiani Yang, Yu Wang. J Ovarian Res 2023
Yongsong Wu, Shilin Xu, Shanshan Cheng, Jiani Yang, Yu Wang. J Ovarian Res 2023
Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context.
Michael P Kolinsky, Karen Y Niederhoffer, Edmond M Kwan, Sebastien J Hotte, Zineb Hamilou, Steven M Yip, Kim N Chi, Alexander W Wyatt, Fred Saad. Can Urol Assoc J 2022
Michael P Kolinsky, Karen Y Niederhoffer, Edmond M Kwan, Sebastien J Hotte, Zineb Hamilou, Steven M Yip, Kim N Chi, Alexander W Wyatt, Fred Saad. Can Urol Assoc J 2022
PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.
Linjie Luo, Khandan Keyomarsi. Expert Opin Investig Drugs 2022
Linjie Luo, Khandan Keyomarsi. Expert Opin Investig Drugs 2022
Poly (ADP-ribose) polymerase inhibitors (PARPi) for advanced malignancies with multiple DNA-repair genetic aberrations.
Jian Hu, Peihe Liang, Dachun Jin, Runze Fan, Xiaodu Xie, Chuan Liu, Qing Jiang, Liang Gao. Expert Rev Anticancer Ther 2022
Jian Hu, Peihe Liang, Dachun Jin, Runze Fan, Xiaodu Xie, Chuan Liu, Qing Jiang, Liang Gao. Expert Rev Anticancer Ther 2022
Guiding ATR and PARP inhibitor combinationswith chemogenomic screens.
Michal Zimmermann, Cynthia Bernier, Beatrice Kaiser, Sara Fournier, Li Li, Jessica Desjardins, Alexander Skeldon, Victoria Rimkunas, Artur Veloso, Jordan T F Young,[...]. Cell Rep 2022
Michal Zimmermann, Cynthia Bernier, Beatrice Kaiser, Sara Fournier, Li Li, Jessica Desjardins, Alexander Skeldon, Victoria Rimkunas, Artur Veloso, Jordan T F Young,[...]. Cell Rep 2022
Targeting DNA damage response pathways in cancer.
Florian J Groelly, Matthew Fawkes, Rebecca A Dagg, Andrew N Blackford, Madalena Tarsounas. Nat Rev Cancer 2022
Florian J Groelly, Matthew Fawkes, Rebecca A Dagg, Andrew N Blackford, Madalena Tarsounas. Nat Rev Cancer 2022
Interstitial brachytherapy combined with PARP inhibitors in the treatment of chemoresistant recurrent epithelial ovarian cancer: A case report.
Yuan Bian, Ping Guan, Dan Li, Longjing Tan, Haowen Pang, Qinglian Wen, Ping Chen, Zhenhua Zhang. Front Oncol 2022
Yuan Bian, Ping Guan, Dan Li, Longjing Tan, Haowen Pang, Qinglian Wen, Ping Chen, Zhenhua Zhang. Front Oncol 2022
PARP Inhibitors in Cancer Diagnosis and Therapy.
Chung Ying Chan, Kel Vin Tan, Bart Cornelissen. Clin Cancer Res 2021
Chung Ying Chan, Kel Vin Tan, Bart Cornelissen. Clin Cancer Res 2021
Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
Sun Young Oh, Shafia Rahman, Joseph A Sparano. Expert Opin Pharmacother 2021
Sun Young Oh, Shafia Rahman, Joseph A Sparano. Expert Opin Pharmacother 2021
Olaparib-mediated enhancement of 5-fluorouracil cytotoxicity in mismatch repair deficient colorectal cancer cells.
Helena de Castro E Gloria, Laura Jesuíno Nogueira, Patrícia Bencke Grudzinski, Paola Victória da Costa Ghignatti, Temenouga Nikolova Guecheva, Natalia Motta Leguisamo, Jenifer Saffi. BMC Cancer 2021
Helena de Castro E Gloria, Laura Jesuíno Nogueira, Patrícia Bencke Grudzinski, Paola Victória da Costa Ghignatti, Temenouga Nikolova Guecheva, Natalia Motta Leguisamo, Jenifer Saffi. BMC Cancer 2021
The role of PARP inhibitors in BRCA mutated pancreatic cancer.
Jeffrey Chi, Su Yun Chung, Ruwan Parakrama, Fatima Fayyaz, Jyothi Jose, Muhammad Wasif Saif. Therap Adv Gastroenterol 2021
Jeffrey Chi, Su Yun Chung, Ruwan Parakrama, Fatima Fayyaz, Jyothi Jose, Muhammad Wasif Saif. Therap Adv Gastroenterol 2021
Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
Mariana Paes Dias, Sarah C Moser, Shridar Ganesan, Jos Jonkers. Nat Rev Clin Oncol 2021
Mariana Paes Dias, Sarah C Moser, Shridar Ganesan, Jos Jonkers. Nat Rev Clin Oncol 2021
Recent Advances in Enhancing the Therapeutic Index of PARP Inhibitors in Breast Cancer.
Camille Franchet, Jean-Sébastien Hoffmann, Florence Dalenc. Cancers (Basel) 2021
Camille Franchet, Jean-Sébastien Hoffmann, Florence Dalenc. Cancers (Basel) 2021
Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Haider Mahdi, Navid Hafez, Deborah Doroshow, Davendra Sohal, Vickie Keedy, Khanh T Do, Patricia LoRusso, Juliane Jürgensmeier, Manuel Avedissian, Jeffrey Sklar,[...]. JCO Precis Oncol 2021
Haider Mahdi, Navid Hafez, Deborah Doroshow, Davendra Sohal, Vickie Keedy, Khanh T Do, Patricia LoRusso, Juliane Jürgensmeier, Manuel Avedissian, Jeffrey Sklar,[...]. JCO Precis Oncol 2021
Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives.
Kai Zimmer, Florian Kocher, Alberto Puccini, Andreas Seeber. Front Oncol 2021
Kai Zimmer, Florian Kocher, Alberto Puccini, Andreas Seeber. Front Oncol 2021
Targeting the DNA damage response: PARP inhibitors and new perspectives in the landscape of cancer treatment.
Sofia Genta, Federica Martorana, Anastasios Stathis, Ilaria Colombo. Crit Rev Oncol Hematol 2021
Sofia Genta, Federica Martorana, Anastasios Stathis, Ilaria Colombo. Crit Rev Oncol Hematol 2021
New Roles of Poly(ADP-Ribose) Polymerase Inhibitors in the Treatment of Breast Cancer.
Elizabeth Harvey-Jones, Gemma Vinas Villaro, Andrew Tutt. Cancer J 2021
Elizabeth Harvey-Jones, Gemma Vinas Villaro, Andrew Tutt. Cancer J 2021
Targeting ATR as Cancer Therapy: A new era for synthetic lethality and synergistic combinations?
Alice Bradbury, Sally Hall, Nicola Curtin, Yvette Drew. Pharmacol Ther 2020
Alice Bradbury, Sally Hall, Nicola Curtin, Yvette Drew. Pharmacol Ther 2020